Disposition of Subjects and Data Sets analyzed.

<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one of the two groups, Group MM (MVA/MVA) or Group PM (Placebo/MVA), respectively, and received at least one vaccination of MVA. All safety data for these 120 subjects were analyzed. * One subject, who didn’t complete the active trial phase returned for the FU visit. ** One subject was excluded from the Immunogenicity Analysis Set (IAS; N = 119), because baseline results were missing. 18 subjects were excluded from the Per-Protocol Set (PPS); N = 102). FU = Follow-up.